“The Swedish register study below confirms that MS is associated with a high-risk of deep vein thrombosis (DVT); typically a clot in the veins of the lower limbs or abdomen. This is not surprising as we already know that immobility, dehydration and intermittent steroid use, which are common in MSers, are know risk factors for DVT and pulmonary embolism or PE (blood clot that has come away from its original site and lodged in the lungs).”
“Only a month ago a husband of one of my patients with SPMS phoned to say that his wife had died suddenly of a pulmonary embolus (PE). He was surprised that they hadn’t been warned about this risk. It made me realise that maybe we should have a system in place to inform all of our patients of the risk of DVT & PE and give then generic advice on how to prevent, or at least reduce the chances, of this potentially fatal complication of MS from happening.”
“To try and lower your risk and help prevent DVT, take these steps:
- Maintain an active lifestyle with regular exercise – daily, if possible. Walking, swimming and cycling, activities that activate the muscles in the calf, that pump the blood to the heart, are appropriate activities.
- Try and maintain a healthy weight – obesity increases your risks of DVT and PE.
- If you smoke, stop. Smoking is another risk factor for thrombosis.
- Report any family or personal history of blood-clotting problems to your MS team.
- Discuss alternatives to birth control pills, or hormone-replacement therapy, with your MS team or GP; these therapies increase your chances of having a DVT.
- Making sure you don’t get dehydrated; this is something MSers do, in particular those who have troubling bladder problems.”
“If you have to travel or sit still for long periods of time your risk of DVT increases. The following may help reduce this risk: wearing compression stockings, avoiding wearing short, tight socks, avoid crossing your legs for long periods, drinking plenty of fluids and avoid dehydrating fluids, such as alcohol, if possible get up and walk around every hour or do regular leg exercises such as leg lifts and gentle foot and ankle exercises. Some guidelines recommend taking a low dose of aspirin (150mg) before travelling, in particular on long-haul flights, but this advice is controversial.”
- pain, swelling and tenderness in one of your legs (usually the calf)
- a heavy ache in the affected area
- warm skin in the area of the clot
- redness of your skin, particularly at the back of your leg below the knee
DVT typically affects one leg, but it can rarely affect both legs simultaneously. The leg pain associated with a DVT may be made worse by bending your foot upward towards your knee. If DVT is not treated, a PE may occur. If you have a PE, you may experience more serious symptoms, such as:
- breathlessness, which may develop gradually or come on very suddenly
- chest pain, which is typically made worse when you breathe in
- sudden collapse
Both DVT and PE are serious conditions that require urgent investigation and treatment.”
Epub: Roshanisefat et al. Multiple sclerosis clinical course and cardiovascular disease risk – Swedish cohort study. Eur J Neurol. 2014 Jul 17.
BACKGROUND AND PURPOSE: Cardiovascular disease (CVD) risk amongst MSers appears raised, but few studies have examined CVD risk amongst an unselected MSer group. MS course may be relevant for CVD risk. Our aim was to assess CVD risk and variation by course in MSers.
METHODS: The Multiple Sclerosis Register identified 7667 MSers who received an MS diagnosis between 1964 and 2005. They were matched by age, period, region and sex with 76 045 members of the general population without MS using Swedish registers. Poisson regression compared the two cohorts to estimate the relative risk for CVD, overall, as well as grouped and individual CVD diagnoses.
RESULTS: MSers had an increased adjusted relative risk (with 95% confidence intervals; number of MS cohort events) for CVD of 1.31 (1.22-1.41; n = 847), with some variation by course: relapsing-remitting 1.38 (1.17-1.62; n = 168); secondary progressive 1.30 (1.18-1.53; n = 405) and primary progressive 1.15 (0.93-1.41; n = 108). The association for the relapsing-remitting course was not significant after excluding the first year of follow-up. Overall incidence rates per 1000 person-years for CVD are 11.8 (11.06-12.66) for the MS cohort and 8.8 (8.60-9.05) for the non-MS cohort. The most pronounced association was for deep vein thrombosis: relapsing-remitting 2.16 (1.21-3.87; n = 14), secondary progressive 3.41 (2.45-4.75; n = 52) and primary progressive 3.57 (1.95-6.56; n = 15). MS was associated with ischaemic stroke but largely during the first year of follow-up. MS was associated with a decreased relative risk for angina pectoris and atrial fibrillation.
CONCLUSIONS: There is a significantly increased relative risk for CVD in MS, particularly for venous thromboembolic disorders in progressive MS, suggesting immobility as a possible factor. An increased frequency of ischaemic stroke in MS is most probably due to surveillance bias resulting from diagnostic investigations for MS. There is no increased relative risk for ischaemic heart disease in MS and atrial fibrillation appears to be less common than amongst the general population.